AEterna Zentaris to Present at Upcoming CIBC World Markets Conference in New York City
March 30 2005 - 11:03AM
PR Newswire (US)
AEterna Zentaris to Present at Upcoming CIBC World Markets
Conference in New York City QUEBEC CITY, Canada, March 30
/PRNewswire-FirstCall/ -- AEterna Zentaris Inc. (TSX: AEZ; Nasdaq:
AEZS) today announced that Gilles Gagnon, President and Chief
Executive Officer of the Company, will present a corporate update
at the CIBC World Markets Annual Biotechnology & Specialty
Pharmaceuticals Conference on Tuesday, April 5, 2005, at 3:45 p.m.
ET, at the Millennium Broadway Hotel in New York City. A live
webcast of the presentation will be available on AEterna Zentaris'
website in the Investors section at http://www.aeternazentaris.com/
. A replay will also be available at the same address for a period
of 30 days. About AEterna Zentaris Inc. AEterna Zentaris Inc. is an
oncology and endocrine therapy focused biopharmaceutical company
with proven expertise in drug discovery, development and
commercialization. The Company's broad 20 product pipeline
leverages five different therapeutic approaches, including LHRH
antagonists and signal transduction inhibitors. The lead LHRH
antagonist compound, cetrorelix, is currently marketed for in vitro
fertilization under the brand name Cetrotide(R). Cetrorelix is also
in late-stage clinical development for endometriosis and benign
prostatic hyperplasia (BPH). The lead signal transduction inhibitor
compound, perifosine, is an orally-active AKT inhibitor that is in
several Phase II trials for multiple cancers. AEterna Zentaris also
owns 61.1% of Atrium Biotechnologies Inc., a leading developer,
manufacturer and marketer of value-added products for the
cosmetics, pharmaceutical, chemical and nutritional industries.
News releases and additional information about AEterna Zentaris are
available on its Web site http://www.aeternazentaris.com/ .
Forward-Looking Statements This press release contains
forward-looking statements made pursuant to the safe harbor
provisions of the U.S. Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and
uncertainties, which could cause the Company's actual results to
differ materially from those in the forward-looking statements.
Such risks and uncertainties include, among others, the
availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the ability
of the Company to take advantage of business opportunities in the
pharmaceutical industry, uncertainties related to the regulatory
process and general changes in economic conditions. Investors
should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information
on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned not to rely on these
forward-looking statements. The Company does not undertake to
update these forward- looking statements. DATASOURCE: AETERNA
ZENTARIS INC. (FORMERLY/ANCIENNEMENT - LES LABORATOIRES AETERNA
CONTACT: Media Relations: Paul Burroughs, (418) 652-8525 ext. 406,
; Investor Relations: Ginette Vallieres, (418) 652-8525 ext. 265, ;
Europe: Matthias Seeber, +49-6942602-3425, ; To request a free copy
of this organization's annual report, please go to
http://www.newswire.ca/ and click on reports@cnw.
Copyright